Pharmaceutical

ADMA Biologics gets grant for treatment of upper respiratory tract infection with immunotherapeutic composition

ADMA Biologics Inc's innovative method for treating upper respiratory infections caused by S. pneumonia with hyperimmune globulin composition.

Apr 11, 2024 - 00:00
ADMA Biologics Inc's innovative method for treating upper respiratory infections caused by S. pneumonia with hyperimmune globulin composition.
Read the original article

Tags:

Previous Article

MorphoSys gets grant for novel compounds for treating diseases associated with m...

Next Article

Kyowa Kirin gets grant for monoclonal antibody inhibiting ccr1 activation by ccl15

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Conflict means millions of children are missing vaccinations, UN says

Conflict means millions of children are missing vaccina...

Jul 16, 2024

STAT+: CVS warns PBM reforms ‘could lead to higher costs’

STAT+: CVS warns PBM reforms ‘could lead to higher costs’

May 31, 2023

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinu...

Jun 20, 2024